Extracellular Vesicles with Dual-Targeting Antibodies for Immune Synapse Formation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face limitations in effectively targeting both cancer cells and immune cells simultaneously, leading to suboptimal activation of immune responses and therapeutic efficacy.
Innovation Solution
Development of multivalent dual-targeted extracellular vesicles with antigen binding domains fused to their surface, which can recognize and bind specific cancer antigens and immune cells, combined with immune checkpoint inhibitors to enhance immunotherapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional immunotherapies are used, then treatment is simple, but they cannot simultaneously target both cancer cells and immune cells effectively
Solution Approach 1:
The patent applies multi-functionality by engineering extracellular vesicles to simultaneously perform multiple functions: targeting cancer cells via tumor-specific antibodies, activating immune cells via immune cell antibodies, and delivering therapeutic payloads. This single vesicle system replaces the need for separate therapeutic agents, achieving dual-targeting capability while managing structural complexity through integrated design.
Solution Approach 2:
The patent merges multiple targeting functions into a single extracellular vesicle platform. By combining cancer cell targeting moieties, immune cell targeting moieties, and therapeutic cargo delivery capabilities within one vesicle structure, the system achieves simultaneous targeting of both cancer cells and immune cells, resolving the contradiction between versatility and complexity.
2Reliability
If multivalent dual-targeted vesicles are used, then immune cell activation is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex multivalent vesicle into modular components: base extracellular vesicle structure, interchangeable targeting moieties (antibodies, ligands), and payload compartments. This modular architecture allows systematic assembly and simplifies manufacturing by enabling independent optimization and quality control of each module before final integration.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying vesicle characteristics such as surface density of targeting moieties, vesicle size distribution, and payload concentration to optimize immune cell activation. These controlled parameter adjustments enable reliable immune response enhancement while maintaining manufacturability through defined production parameters.
3Measurement precision
If geometrically and orientationally defined antigen-binding arms are used, then binding specificity is high, but synapse formation potential is limited
Solution Approach 1:
The patent applies dimensionality change by transitioning from the fixed, linear geometry of conventional antibody antigen-binding arms to the three-dimensional spherical surface of extracellular vesicles. This spherical geometry provides multiple binding interfaces and flexible orientation, enabling simultaneous high-specificity binding and enhanced immunological synapse formation by engaging multiple immune cell receptors in spatial configurations that linear antibodies cannot achieve.
Solution Approach 2:
The patent utilizes spheroidality by employing the curved spherical surface of extracellular vesicles as the platform for antigen binding. This curved geometry allows multiple targeting moieties to be distributed across the surface in optimal orientations, simultaneously maintaining binding specificity through precise antigen recognition and enhancing synapse formation through the three-dimensional contact interface with immune cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered vesicles promote the formation of immunological synapses and significantly enhance the activation of immune cells, offering improved therapeutic outcomes and safety as novel nanomedicines for cancer and other diseases.
Implementation Method 1
the one or more antigen binding domains are selected from the group of: an antibody, a multi-specific antibody, a monoclonal antibody, an scFv antibody fragment, a single domain antibody
Data Source
AI summary
Given developing resistance of tumor cells to current chemotherapeutic and targeted therapeutic agents, novel cancer therapies with enhanced potency and specificity are substantially required. Applicant has provided herein extracellular nanoparticle vesicles that redirect immune effector cells towards cancer cells for killing. Relative to conventional immunotherapeutic antibodies with defined orientation and geometry for their distinct antigen-binding arms, antibodies displayed on spherical exosomes can promote formation of immunological synapses as well as enhanced efficacy to activate immune cells.